Episodic migraine
Conditions
Brief summary
Change in number of migraine days from screening period (week -4 –baseline) to week 8–12.
Detailed description
Incidence of adverse events (AEs) and serious adverse events (SAEs) at 16 weeks, Suspected unexpected serious adverse reaction (SUSAR)., Withdrawals, Intensity and duration, Type and dose of medication, Self-assessed efficacy of rescue treatment, ≥50% reduction in attack frequency (week -4 –baseline) to week 8–12, Numbers of patients within each category at 12 weeks, Reported IgE value at baseline and 16 weeks, Change in number of migraine days from screening period (week -4 –baseline) to week 12–16
Interventions
DRUGXolair 300 mg solution for injection in pre-filled syringe
Sponsors
Oslo University Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in number of migraine days from screening period (week -4 –baseline) to week 8–12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AEs) and serious adverse events (SAEs) at 16 weeks, Suspected unexpected serious adverse reaction (SUSAR)., Withdrawals, Intensity and duration, Type and dose of medication, Self-assessed efficacy of rescue treatment, ≥50% reduction in attack frequency (week -4 –baseline) to week 8–12, Numbers of patients within each category at 12 weeks, Reported IgE value at baseline and 16 weeks, Change in number of migraine days from screening period (week -4 –baseline) to week 12–16 | — |
Outcome results
None listed